Expanded Access to L-MTP-PE for the Treatment of Osteosarcoma

Full Title

Purpose

This protocol will provide expanded access to treatment with the investigational drug L-MTP-PE for people with osteosarcoma. L-MTP-PE works by activating certain types of white blood cells, and these active white blood cells help the immune system to kill cancer cells. L-MTP-PE is given intravenously (by vein).

Who Can Join

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

• Patients much have osteosarcoma which has been entirely surgically removed or is in complete remission.
• This study is for patients of all ages.

For more information about this study and to inquire about eligibility, please contact 1-833-MSK-KIDS.